Biosimilar Guidances Under Review, Sponsor Meetings Continue

Washington Drug Letter
A A
Even though the FDA hasn’t released details on how its abbreviated approval pathway for biosimilars will work, the agency has already held 21 pre-IND meetings on 11 reference biologics and received seven INDs, said Leah Christl, CDER’s associate director for biosimilars.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00